NTLA$9.2101
Chart
Performance
Key Stats
AI NTLA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralIntellia Therapeutics is in the rapidly growing gene editing sector, offering significant long-term thematic potential. However, current financial performance shows substantial losses, and technical indicators are mixed, suggesting a neutral outlook for the near to medium term.
Thematic
Intellia Therapeutics is at the forefront of gene editing, a transformative technology with the potential to revolutionize medicine. Its focus on in vivo therapies and a strong pipeline of treatments for serious diseases positions it well for substantial growth.
Fundamental
Intellia Therapeutics is a clinical-stage company with no revenue generation from approved products, leading to significant net losses and negative earnings. While it has substantial cash reserves, its profitability metrics are currently very weak.
Technical
The stock is trading above key moving averages, indicating a generally bullish trend. However, some oscillators suggest potential overbought conditions, and recent performance has been volatile, leading to a neutral technical rating.
| Factor | Score |
|---|---|
| Gene Editing Technology | 95 |
| Pipeline Strength | 85 |
| Market Growth Potential | 90 |
| Strategic Partnerships | 85 |
| Competitive Landscape | 85 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 60 |
| Balance Sheet Health | 75 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 50 |
| Short-term Oscillators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Short-Term Performance
The stock has shown positive performance over the last 1 month (+30.98%) and 6 months (+21.23%), indicating recent investor interest.
Bullish Momentum Indicators
Several short-term technical indicators, such as Stochastic %K, Commodity Channel Index, and Stochastic RSI Fast on the 1m and 5m charts, suggest a 'Buy' signal.
Bearish Points (8)
Significant Net Losses
The company has consistently reported substantial net losses, with a TTM net income of -378.94 million and a net margin of -896.8% in Q4 2024, indicating a lack of profitability.
High Price to Earnings (P/E) Ratio
The TTM P/E ratio is -3.3, and the annual P/E for 2024 is -2.3, reflecting negative earnings which makes traditional P/E analysis unreliable and suggests potential overvaluation given the losses.
Calendar
August 2025
11
Next Earnings Date
H: $-0.61
A: $-1.01
L: $-1.30
H: 50.00M
A: 12.26M
0Profile
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
37.30 USD
The 39 analysts offering 1 year price forecasts for NTLA have a max estimate of 106.00 and a min estimate of 7.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in CRISPR/Cas9 gene editing, developing treatments for similar genetic blood disorders and in vivo targets.
Weight: 95
Leading company in base editing, a next-generation precision gene editing technology closely related to CRISPR, targeting similar diseases.
Weight: 92
Direct competitor in CRISPR/Cas9 gene editing, with pipelines focused on ocular diseases and ex vivo cell therapies.
Weight: 90
Pioneering in vivo gene editing for cardiovascular diseases, utilizing base editing and other gene editing tools, often considered a direct peer.